Latest news
Loading news…
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Rapt Therapeutics was acquired by GSK in 2026 for $2B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
90
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- South San Francisco, California, United States
Key People at Rapt Therapeutics
Senior Director, Quantitative Biology
Senior Vice President of Quantitative and Computational Biology
President and CEO
Chief Scientific Officer
Chief Financial Officer
Sen. VP Discovery and Preclinical Development
90
professional contacts at Rapt Therapeutics
Contact execs at Rapt Therapeutics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Rapt Therapeutics
Loading news…
FAQs about Rapt Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.